HURA: Third Quarter Results [Yahoo! Finance]
TuHURA Biosciences: Potential In Immunotherapy Resistance, But How Will It Be Funded? [Seeking Alpha]
TuHURA Biosciences (NASDAQ:HURA) had its price target lowered by analysts at Maxim Group from $15.00 to $8.00. They now have a "buy" rating on the stock.
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update